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Abstract Various herbal medicines have been developed
and used in various parts of the world for thousands of
years. Although locally grown indigenous plants were
originally used for traditional herbal preparations, Western
herbal products are now becoming popular in Japan with
the increasing interest in health. At the same time, there are
growing concerns about the substitution of ingredients and
adulteration of herbal products, highlighting the need for
the authentication of the origin of plants used in herbal
products. This review describes studies on Cimicifuga and
Vitex products developed in Europe and Japan, focusing on
establishing analytical methods to evaluate the origins of
material plants and finished products. These methods
include a polymerase chain reaction-restriction fragment
length polymorphism method and a multiplex amplification
refractory mutation system method. A genome-based
authentication method and liquid chromatography-mass
spectrometry-based authentication for black cohosh prod-
ucts, and the identification of two characteristic diterpenes
of agnus castus fruit and a shrub chaste tree fruit-specific
triterpene derivative are also described.
Keywords Herbal product · Quality control · DNA
identification · LC/MS · Cimicifuga · Vitex
Introduction
Herbal medicines have been used for thousands of years
to treat illness in various parts of the world. Kampo
medicines (traditional Japanese medicines) were devel-
oped in Japan using herbal plants native to Asia, whereas
Western herbal plants native to Europe have traditionally
been used as crude drugs. The raw materials and extracts
are now standardized to be used for medicines in many
countries. Thus, closely related plants are used worldwide
for different pharmaceuticals with different treatment
applications, depending on their background. For exam-
ple, the flowering aerial part of Leonurus cardiac L. is
used to relieve symptoms of nervous tension under the
name ‘motherwort’ in Europe, whereas the flowering
aerial part of L. japonicas Houtt. and L. sibiricus L. is
used as a crude drug named Leonurus Herb (益母草 in
Japanese) as a component of Kampo formulations for the
treatment of women’s disorders in Japan (Table 1). When
herbal medicines are made from locally grown plants
there is less concern, but misidentification and confusion
may occur when both Western and the Asian herbal
medicines are used in the same area.
In Japan, Western herbal preparations have only been
used as health food products because of the lack of
usage experience but they now are becoming more
popular due to the changes in cause-specific morbidity
and the increasing interest in self-medication. After
guidelines for the approval of pharmaceuticals including
Western herbs were established based on a notification
from the Japanese Ministry of Health, Labour and
Welfare [1], two products prepared from Western herbs
have been approved as over-the-counter (OTC) drugs in
Japan, and more products are expected to become
available to the Japanese market in the near future.
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Practical methods for verifying the botanical sources of
herbal products are thus required to ensure the safety and
efficacy of such products [2–4]. This review describes
some of our recent studies on the genetic and chemical
authentication of the original plant species in herbal
products.
Studies on the botanical origins of Cimicifuga
products
Black cohosh (Cimicifuga racemosa (L.) Nutt.) is one of the
most commonly used Western herbs today. Its roots and
rhizomes have traditionally been used for the treatment of
women’s disorders in North America and Europe, and it is
now used globally to alleviate menopausal symptoms, being
one of the top 10 best-selling herbs in the USA. Black
cohosh extracts or materials are officially prescribed in the
European Pharmacopoeia (EP) and standardized as an active
ingredient of OTC drugs in Europe. In the USA, black
cohosh extracts and materials are prepared for use as dietary
supplements, and The United States Pharmacopeia and The
National Formulary (USP−NF) provides the standards.
Because the regulation of herbal products as dietary
supplements in the USA is less strict than for OTC drugs in
Europe, the substitution and adulteration of black cohosh
dietary supplements with related Cimicifuga plants has
frequently occurred in North America [5–7]. Additional
reports have described hepatotoxicity associated with the
use of black cohosh products, especially from products
derived from the wrong plant parts instead of the roots and
rhizomes or different Cimicifuga species [8–12]. The
Ministry of Health, Labour and Welfare of Japan as well as
other national ministries have updated their notifications
about the risk of adverse liver reactions caused by the use
of products containing black cohosh.
One possible reason why Cimicifuga plants native to
Asia have been found in dietary supplements in the USA is
that Chinese crude drugs were mistakenly recognized as
black cohosh and were mixed with it. Cimicifuga plants are
also used as traditional medicines in East Asia including
Japan; the rhizome of C. dahurica (Turcz.) Maxim.,
C. foetida L. and C. heracleifolia Kom. is defined in the
Chinese Pharmacopoeia (CP) as a crude drug named
Cimicifuga Rhizome with heat-clearing and detoxifying
effects, whereas the Japanese Pharmacopoeia (JP)
describes C. simplex (DC.) Wormsk. in addition to the
above three species as the botanical origin of Cimicifuga
Rhizome (or “升麻” in Japanese) [13]. It is illegal in Japan
for any health foods to contain materials or extracts pre-
pared from C. simplex, C. dahurica, C. foetida or
C. heracleifolia instead of C. racemosa, because Cimi-
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Because of these problems, we developed genetic and
chemical methods to simultaneously discriminate C. race-
mosa from other related species for the evaluation of
black cohosh products that are commercially available in
Japan.
Genome-based authentication of black cohosh
products
Molecular biological techniques are useful and powerful
methods to detect genetic differences among closely
Table 2 Genetic identification of referential Cimicifuga plant samples
Sample
ID
Plant species ITS region Registered GenBank
accession no.










C1 C. rubifolia Z98297 99 AB987680 AJ223004 98 AB987688
C2 C. japonica Z98291 98 AB987681 AJ222999 98 AB987689
C3 C. simplex Z98299 99 AB987682 AJ223008 98 AB987690
C4 C. simplex Z98299 99 AB987683 AJ223008 98 AB987691
C5 C. simplex AB044408 96 AB987684 AJ223008 98 AB987692
C6 C. dahurica Z98284 99 AB987685 AJ222992 98 AB987693
C7 C. heracleifolia Z98290 97 AB987686 EU186382 97 AB987694
C8 C. racemosa Z98296 99 AB987687 AJ223003 98 AB987695
Fig. 1 Partial ITS sequences
observed in referential
Cimicifuga plants. Sequence
data are deposited in GenBank
under accession nos.
AB987680–AB987687. Bold
the sequence recognized by
BstBI
500 bp
Fig. 2 PCR-RFLP analysis of Cimicifuga plants showing the
restriction enzyme BstBI on a partial ITS region. Data taken from
reference 20. The forward primer: 5′-ATCATCCATTGTCGGGT
CAT-3′, the reverse primer: 5′-GTTTACAACCACCGCAGACC-3′.
Sample IDs are shown in Table 2. M 100 bp DNA ladder, D digested,
U undigested
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related plant species [14–17]. For Cimicifuga plants, a
random amplified fragment length polymorphism finger-
printing method was developed to identify the four
sympatric species distributed in eastern North America
(C. racemosa, C. americana Michx., C. pachypoda Elliott
and C. rubifolia Kearney) [18], and a multiplex amplifi-
cation refractory mutation system (ARMS) method was
developed to identify four Asian species (C. dahurica,
C. foetida, C. heracleifolia, and C. simplex) [19]. To the
best of our knowledge, there has been no report about the
simultaneous identification of both North American and
Asian species. To establish a DNA analytical method that
can discriminate C. racemosa from possible contaminated
species, we prepared six Cimicifuga plants, identified each
species by sequencing, and attempted to develop poly-
merase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) and ARMS methods [20].
Eight referential Cimicifuga plants were kindly provided
by the Research Center for Medicinal Plant Resources,
National Institute of Biomedical Innovation, Health and
Fig. 3 Partial trnL-F gene
sequences observed in
referential Cimicifuga plants.
The sequence data were




M     C1   C2    C3   C4   C5    C6   C7   C8 
500 bp
(b) 
M     C1   C2    C3    C4   C5    C6    C7   C8 
500 bp
Fig. 4 ARMS analysis of Cimicifuga plants in trnL−trnF IGS region.
Data taken from reference 20. a PCR amplification using a specific
primer set for C. racemosa. b PCR amplification using a primer set for
other Cimicifuga species. The sequences of a species-specific sense
primer for C. racemosa and another five Cimicifuga species: 5′-C
CTGAGCCAAATCCTGTTCTA-3′ and 5′-CCTGAGCCAAATCCT
GTTCTC-3′. The sequence of a common anti-sense primer: 5′-TCA
AATCAGCCACTCCATAGTATGA-3′. Sample IDs are shown in





Fig. 5 ARMS analysis of black cohosh products using the partial
trnL gene. Data taken from reference 20. a PCR amplification using a
specific primer set for C. racemosa. b PCR amplification using a
primer set for other Cimicifuga species. B1, 2, 3, 4 and 6 contained
powdered dried material within the capsules, whereas B5, 7, and 8
contained both powdered material and dry extract within the capsules.
N no template control, M 100 bp DNA ladder
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actein (1) 23-epi-26-deoxyactein (2)
Fig. 6 Chemical structures of actein and 23-epi-26-deoxyactein. Xyl β-D-xylopyranosyl
Table 3 The Cimicifuga products applied for LC/MS analysis
Sample ID Classa Content Source plantb XIC pattern Predicted species
BC-1 A Powdered plant material C. racemosa I
BC-2 A Dry extract I C. racemosa
BC-3 A Powdered plant material C. racemosa I
BC-4 A Powdered plant material and dry extract C. racemosa I
BC-5 A Dry extract IV Others
BC-6 A Powdered plant material C. dahurica II
BC-7 A Powdered plant material and dry extract C. dahurica III
BC-8 A Dry extract I C. racemosa
BC-9 A Powdered plant material and dry extract C. racemosa I
BC-10 A Dry extract I C. racemosa
BC-11 A Dry extract I C. racemosa
BC-12 A Powdered plant material C. dahurica II
BC-13 A Dry extract I C. racemosa
BC-14 A Dry extract I C. racemosa
BC-15 A Powdered plant material C. racemosa I
BC-16 A Powdered plant material and dry extract C. dahurica III
BC-17 A Dry extract I C. racemosa
BC-18 A Dry extract IV Others
BC-19 A Powdered plant material and dry extract C. dahurica III
BC-M1 B Dry extract I C. racemosa
BC-M2 B Dry extract I C. racemosa
BC-M3 B Dry extract I C. racemosa
BC-M4 B Dry extract I C. racemosa
BC-M5 B Dry extract I C. racemosa
BC-M6 B Dry extract I C. racemosa
CR-1 C Cut crude drug C. dahurica II
CR-2 C Cut crude drug C. dahurica II
CR-3 C Cut crude drug C. dahurica, C. heracleifolia II
CR-4 C Cut crude drug C. dahurica II
CR-5 C Cut crude drug C. dahurica II
a A health food, B OTC drug of EP grade, C crude drug of JP grade
b The species of plant materials were identified by DNA sequencing
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Nutrition, and were identified as six species (one C. race-
mosa, three C. simplex and one each of C. japonica (Thunb.)
Spreng, C, dahurica, C. heracleifolia and C. rubifolia) by
DNA sequencing on the ITS and trnL−F regions (Table 2).
Based on these sequences and sequences obtained from the
DNA databases, we first developed a novel PCR-RFLP
method for the identification of C. racemosa targeting on its
unique BstBI restriction site (5´ TT*CGAA 3′) on the ITS1
region (Fig. 1). When the 441 bp of a DNA fragment on the
ITS1 region was amplified by PCR from referential plant
samples and digested with BstBI, two unique fragments of
134 and 307 bp were observed only from the referential
C. racemosa plants (Fig. 2).
Although we found this to be a convenient and useful
method to identify species of plant samples and to detect
the presence of C. racemosa in black cohosh products, we
could not detect contaminated or adulterated products by
this method because undigested fragments remained.
Therefore, we next developed an ARMS method for dis-
criminating C. racemosa from other related species, using
two types of specific sense primers targeting the nucleotide
substitution at position 61 on the trnL gene (Fig. 3). The
species-specific and the common fragments (284 bp) were
successfully observed from C. racemosa and the other five
species when the PCR was performed with DNAs from
referential plants using the specific primer sets for
C. racemosa and those for others, respectively (Fig. 4). Our
results indicated that the ARMS analysis was a more
accurate method than the PCR-RFLP method to identify
C. racemosa from the related species, although the ARMS
method takes a longer time.
We then applied the ARMS method to test the original
plants of eight black cohosh products available on the
Japanese market, and the results demonstrated that three of
the eight products were not derived from C. racemosa
(Fig. 5; Table S1). We also performed TLC and HPLC
analyses for detecting two marker compounds—actein (1)
and 23-epi-26-deoxyactein (2)—(Fig. 6) from black cohosh
products, and we found that the three of the eight products
Fig. 7 Representative XIC of black cohosh samples classified as patterns I, II, and III. Data taken from reference 22. 1R: (R)-actein, 1S: (S)-
actein
Fig. 8 Chromatograms of ACF and SCTF samples. Data taken from
reference 24. Two samples of ACF available in Germany and five
samples of SCTF in Japan were derived from V. agnus-castus and V.
rotundifolia or their mixture with V. trifolia, respectively. a TIC of
ACF and SCTF samples. b XIC of ACF and SCTF samples at m/z
335.22–335.23. The MS and MS/MS spectra of peak ID 1552 from
ACF-2 are shown in the upper-right window
▸
366 J Nat Med (2016) 70:361–375
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did not contain marker compounds, as was also shown by
the results of the ARMS analysis (data not shown). These
TLC and HPLC results completely followed the results of
the ARMS analysis and strongly demonstrated that the
ARMS analysis is a useful method for authenticating the
botanical source of black cohosh products.
LC/MS-based authentication of black cohosh
products
Although the ARMS analysis was a very precise and
straightforward way to evaluate the botanical origin of
black cohosh products as described above, it had a disad-
vantage in that hardly any DNA was obtained from the
products consisting of dry extracts. On the other hand,
chemical analyses using marker compounds were also
difficult to use for evaluating the botanical origin because
most of the metabolites from closely related plant species
overlap. The EP sets an identification test for black cohosh
to confirm the presence of actein (1) and 23-epi-26-
deoxyactein (2) by TLC. However, since these compounds
are present in other Cimicifuga species as well as C. race-
mosa, the EP sets three additional TLC tests for
substitution and adulteration to compare the chromatogram
Table 4 Comparison of 1H- and 13C-NMR data between Ref. and
compounds 3/3a in chloroform-d (800 and 200 MHz, δ in ppm, J in
Hz)
Position LA/LB*1 (5:2 mixture) 3/3a (4:1 mixture)
δ δ
1 1.86 (1H, m)
1.44 (1H, dt, 12.5, 3.7)
CH2 (29.9/28.7)
1.56 (overlapping)
1.41 (1H, dd,10.4, 4.8)
CH2 (30.4/30.3)
2 1.64-1.68 (1H, m)





3 3.11 (1H, dd, 11.6, 4.3)/3.07




0.97 (1H, ddd-like, 12.8,
6.3, 4.0)
CH2 (41.5/41.5)
4 C (37.4/37.4) C (31.2/30.9)
5 2.63 (1H, s)/2.64 (1H, s)
CH (58.5/58.1)
2.51 (1H, s)/2.62 (1H, s)
CH (58.2/57.6)
6 C (210.3/210.6) C (210.5/210.6)
7 2.41 (1H, td, 13.1, 0.9)/2.36 (1H,
td, 13.1, 1.0)




2.00 (1H, td, 12.8, 4.8)
CH2 (47.6/47.8)




9 C (92.7/93.0) C (91.9/91.8)
10 C (47.3/47.5) C (46.4/46.8)
11 2.14 (1H, dd, 9.4, 3.6)
1.83 (1H, m)
CH2 (29.0/31.2)
2.17 (1H, ddd, 13.0, 8.8,
3.2)
1.83 (1H, ddd, 13.0, 9.6,
4.8)
CH2 (28.0/27.6)
12 2.02 (1H dd, 9.1, 3.6)
1.92 (1H, dd, 9.1, 4.3)
CH2 (36.6/37.2)




13 C (91.3/92.5) C (90.3/91.7)
14 2.43 (1H, dt, 11.9, 9.8)
1.92 (1H, ddd, 11.9, 7.3, 2.7)
CH2 (35.5/31.1)
2.43 (1H, ddd, 12.5, 9.6,
2.4)
1.94 (1H, ddd, 12.5, 7.2,
3.2)
CH2 (34.6/35.9)
15 4.11 (1H, ddd, 9.8, 8.7, 2.7)/4.04
(1H, td, 8.5, 3.9)
3.79 (1H, td, 8.7, 7.3)/3.97 (1H,
td, 8.5, 7.0)
CH2 (64.8/66.3)
4.13 (1H, ddd, 9.6, 8.8,
3.2)/4.06 (1H, m)
3.77 (1H, ddd, 8.8, 7.2,
2.4)/4.00 (1H, m)
CH2 (64.0/65.5)
16 4.81 (1H, s)/5.33 (1H, s)
CH (99.0/101.6)
4.78 (1H, s)/5.37 (1H, s)
CH (98.1/100.6)
17 0.95 (3H, d, 6.4)/0.96 (3H, d,
6.4)
CH3 (16.9/17.6)
0.93 (3H, d, 6.4)
CH3 (16.0/16.7)
18 1.08 (3H, s)/1.07 (3H, s)
CH3 (27.7/27.6)
0.91 (3H, s)/0.89 (3H, s)
CH3 (31.7/31.6)
Table 4 continued
Position LA/LB*1 (5:2 mixture) 3/3a (4:1 mixture)
δ δ
19 1.16 (3H, s)/1.15 (3H, s)
CH3 (14.9/15.0)
1.14 (3H, s)/1.18 (3H, s)
CH3 (20.8/21.7)
20 0.88 (3H, s)/0.87 (3H, s)
CH3 (20.0/20.2)
0.81 (3H, s)/0.86 (3H, s)
CH3 (19.0/19.2)
16-OH 3.18 (1H, br s)*2
*1 LA leucasperol A, LB leucasperol B; a pair of signals from tau-
tomers is shown as ‘LA/LB’
*2 Disappeared upon treatment with heavy water
R1=OH R2=H  chastol (3)
R1=H R2=OH  epichastol (3a)
Fig. 9 Chemical structures of chastol and epichastol
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obtained from the reference solution with each chro-
matogram from C. americana, C. foetida, and the mixture
of C. dahurica and C. heracleifolia [21].
In the course of our studies on the botanical origins of
black cohosh products, we found and reported a simple
way to detect substitution and adulteration [22]. We
prepared 25 black cohosh products including six OTC
drugs purchased in Europe (Table 3: BC-1 to -19, BC-
M1 to –M6) and five Cimicifuga Rhizome crude drugs
of JP grade (Table 3: CR-1 to -5), and we genetically
identified their origins by DNA sequencing and analyzed
their constituents by liquid chromatography-mass spec-
trometry (LC/MS). The sequencing analysis of the ITS
region revealed that five of the 10 tested health food
products containing powdered plant material contained
undeclared C. dahurica, and that Cimicifuga Rhizome
products were derived from C. dahurica except for CR-
3, which contained both C. dahurica and C. heracleifolia
(Table 3).
When these 15 samples were analyzed by LC/MS for the
detection of actein (1) and 23-epi-26-deoxyactein (2), they
showed three chromatographic patterns (I, II and III) based
on the extracted ion chromatograms (XIC) at m/z 735.4
corresponding to actein (Fig. 7). All of the black cohosh
products derived from C. racemosa (BC-1, -3, -4, -9, and -
15) definitely contained marker compounds and showed
pattern I. Of the 10 products that contained plant materials
of C. dahurica, all of the Cimicifuga Rhizome samples
(BC-6 and BC-12) showed pattern II, whereas the chro-
matograms of the other black cohosh samples (BC-7, -16,
and -19) showed pattern III.
Pattern III appears to overlap with patterns I and II, and
the products of pattern III consisted of powdered materials
and dry extracts; it was thus strongly suggested that BC-7, -
16 and -19 consisted of powdered materials of C. dahurica
and an extract prepared from C. racemosa. Taking these
results together with our above-described findings, we
speculated that patterns I, II, III represent their botanical
origins as C. racemosa, C. dahurica and the above-de-
scribed mixture, respectively. We therefore established a
simple method to detect substitution and adulteration of
black cohosh products by monitoring a specific mass range
on LC/MS.
We then analyzed the other black cohosh samples
(which consisted only of dry extracts) by LC/MS to eval-
uate their botanical origins, and we found that 13 products
including OTC drugs correctly used the dry extract of
C. racemosa, and we observed that the XIC from BC-5 and
BC-18 were out of synchronization with all three patterns
(Table 3). Our finding that all the OTC drugs of EP grade
Fig. 10 Extracted ion chromatograms of the processed ACF samples at m/z 335.22–335.23. Data taken from reference 24. ACF-11, -12 and -13
were available in Europe as OTC drugs of EP grade and ACF-21 and -22 produced in the USA were available in Japan as health food products
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were classified in the pattern I group strongly supports the
usefulness of this method. The use of our new method
could thus be a possible solution to the problem of adul-
teration of black cohosh products available in Japan.
Studies of the botanical origins of Vitex products
The dried ripe fruit of Vitex agnus-castus L. is defined










































Fig. 11 OPLS-DA/O2PLS plots based on the LC/MS data of the
SCTF and ACF products. Data taken from reference 30. Four samples
of SCTF were crude drugs of non-JP grade with dried fruit form.
ACF-101 and -102 were crude drugs of EP grade with dried fruit
form. ACF-103 and -104 were health food with capsule form. a Score
plot of SCTF and ACF products. Black circles ACF. Open squares
SCTF. b S-plot of SCTF and ACF products
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Table 5 Comparison of 1H-
NMR data between compound 4
and Ref. in methanol-d4
(800 MHz, δ in ppm, J in Hz)
Position 4 Ref.*1
δ δ
2 3.84 (1H, ddd, J = 4.0, 10.4, 11.2) 3.85 (1H, ddd, J = 4.4, 9.9, 11.0)
3 4.64 (1H, d, J = 10.4) 4.64 (1H, d, J = 9.9)
12 5.29 (1H, t, J = 3.0) 5.30 (1H, br s)
18 2.51 (1H, s) 2.51 (1H, br s)
23 0.90 (3H, s) 0.90 (3H, s)
24 0.95 (3H, s) 0.96 (3H, s)
25 1.05 (3H, s) 1.06 (3H, s)
26 0.82 (3H, s) 0.81 (3H, s)
27 1.36 (3H, s) 1.97*2 (3H, s)
29 1.20 (3H, s) 1.20 (3H, s)
30 0.93 (3H, d, J = 6.4) 0.93 (3H, d, J = 6.6)
2′ 6.43 (1H, d, J = 16.0) 6.43 (1H, d, J = 16)
3′ 7.62 (1H, d, J = 16.0) 7.63 (1H, d, J = 16)
2′’ 7.20 (1H, d, J = 1.6) 7.21 (1H, br s)
5′’ 6.81 (1H, d, J = 8.0) 6.81 (1H, d, J = 7.7)
6′’ 7.07 (1H, dd, J = 1.6, 8.0) 7.08 (1H, br d, J = 7.7)
OCH3 3.89 (3H, s) 3.90 (3H, s)
Data taken from reference 30
*1 Zhao Q-C, Cui C-B, Cai B, Yao X-S, Osada H, Molbank, M328 (2003)
*2 May be mistyped
Table 6 13C-NMR data of compound 4 in methanol-d4 (200 MHz, δ
in ppm)
Position 4 Ref.*1 Position
δ DEPT δ
1 48.2 CH2 48.55
2 67.8 CH 67.65
3 85.8 CH 85.64
4 40.8 C 40.65
5 56.6 CH 56.46
6 19.8 CH2 19.58
7 34.2 CH2 34.03
8 42.9 C 42.68
9 48.8 CH 8.71*2
10 39.4 C 39.00
11 24.9 CH2 24.75
12 129.2 CH 129.14
13 140.5 C 140.16
14 41.3 C 41.14
15 29.8 CH2 29.59
16 26.8 CH2 26.60
17 49.3 C 48.72
18 55.3 CH 55.09
19 73.8 C 73.57
20 43.3 CH 43.09
21 27.5 CH2 27.30
22 39.3 CH2 39.22
Table 6 continued
Position 4 Ref.*1 Position
δ DEPT δ
23 29.4 CH3 29.25
24 18.5 CH3 18.32
25 17.3*3 CH3 16.60
26 17.7*3 CH3 17.07
27 25.0 CH3 24.83
28 182.9 C 182.29
29 27.2 CH3 27.05
30 16.8*3 CH3 17.50
1′ 169.8 C 169.61
2′ 116.3 CH 116.16
3′ 146.7 CH 146.50
1″ 128.1 C 127.90
2″ 111.8 CH 111.58
3″ 149.6 C 149.40
4″ 150.7 C 150.53
5″ 116.7 CH 116.49
6″ 124.3 CH 124.04
OCH3 56.7 CH3 56.51
Data taken from reference 30
*1 Zhao Q-C, Cui C-B, Cai B, Yao X-S, Osada H, Molbank, M328
(2003)
*2 May be mistyped
*3 Assigned from HMBC correlations
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tree, respectively, in the EP and USP−NF. ACF is used to
treat symptoms of premenstrual syndrome and climacteric
disorder, and it is becoming popular in Japan as the active
ingredient of OTC drugs and health food products. On the
other hand, the fruit of its congenic species, V. rotundifolia
L. f. and V. trifolia L., has been used as a crude drug named
shrub chaste tree fruit (SCTF) (蔓荊子 in Japanese) for its
pain relief, sedative and anti-inflammatory effects.
Although the EP sets an identification test for ACF to
confirm the presence of aucubin and agnuside by TLC as
well as a purity test by macroscopic analysis based on the
size of the fruit to distinguish V. agnus-castus from other
Vitex species [23], the chemical components and morpho-
logical characteristics of Vitex species are too similar to
discriminate between them. Considering the international-
ization of the supply chain of herbal plants, this situation
could lead to misidentification of the botanical origin of
these crude drugs, resulting in unexpected adverse reac-
tions as well as a decline in their pharmaceutical efficacy.
We therefore attempted to identify the marker compounds
that distinguish ACF and SCTF with the goal of estab-
lishing quick methods to evaluate their origins.
Identification of characteristic diterpenes of ACF
We first prepared crude drugs of ACF of EP grade and
SCTF of Japanese standards for non-pharmacopoeial crude
drugs (non-JP) grade to confirm their origins by DNA
sequencing, and we applied them in a differential analysis
using LC/MS data [24]. The sequencing analysis of the
LFY/FLO gene revealed that two samples of ACF available
in Germany and five samples of SCTF in Japan were
derived from V. agnus-castus and V. rotundifolia or its
mixture with V. trifolia, respectively (Table S2). To identify
candidate marker compounds for ACF against SCTF, we
performed a high-resolution LC/MS analysis of crude drug
samples in an automated differential analysis, and we
obtained 23 peaks as candidates. We then filtered these
candidates on the basis of each formula and intensity, and
seven peaks were finally picked up as characteristic com-
pounds for ACF.
The chemical formulas calculated based on the accurate
mass and MS fragmentation pattern of these peaks were
collated with the phytochemical metabolite database, and
we selected a putative diterpene with a novel structure—ID
1552 (RT 19.02 min, m/z 335.2228, formula C20H31O4 for
[M-H]−)—as the first target to identify the chemical
structure (Fig. 8). An ACF health food product was used as
a source material of peak ID 1552. The repeated column
chromatography and preparative TLC of a CHCl3 extract
of the ACF health food product afforded compound 3/3a as
a mixture. Compound 3/3a was obtained as a white pow-
der. The 1H-NMR and 13C-NMR spectroscopic data of 3/
3a (Table 4) were very similar to those of known com-
pounds, leucasperols A and B [25], and the complete
structures of 3/3a were determined on the basis of the
spectroscopic data from HMBC, COSY, NOESY and dif-
ferential NOE NMR experiments (Fig. 9). Since there have
been no reports on the isolation of compounds bearing this
structure other than leucasperols A and B from Leucas
aspera L., we proposed the trivial names chastol and
epichastol for compounds 3 and 3a, respectively.
We analyzed additional ACF products by LC/MS to
verify the usefulness of 3/3a as marker compounds, and we
successfully confirmed their detection (Fig. 10; Table S3).
Since avoiding contamination from closely related species
is a significant requirement for pharmaceuticals of natural
origin, this information will be valuable for the quality
control of both ACF and SCTF products from the view-
point of regulatory science.
Fig. 12 Chemical structure of
3-O-trans-feruloyl tormentic
acid
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Identification of an SCTF-specific triterpene
derivative
Metabolomics have recently been adopted for the classifi-
cation of variables and the identification of marker
compounds based on the characteristics of their metabolic
profiles in phytochemical investigations. For example,
chemometric analyses such as a principal component
analysis, a partial least-squares discriminant analysis, and
an orthogonal partial least-squares discriminant analysis
(OPLS-DA) are frequently used as multivariate tools for
discrimination analyses [26–29]. In order to identify mar-
ker compounds for SCTF against ACF, we analyzed SCTF
and ACF products by LC/MS to apply to multivariate
analyses [30].
When the LC/MS data set was subjected to OPLS-DA,
the clusters of SCTF and ACF were clearly separated on
the score plots, and 28 ions were picked up as the most
influential variables that contribute to the segregation of
SCTF and ACF samples on the S-plots (Fig. 11; Table S4).
We then filtered these candidates on the basis of each
formula and intensity, and seven peaks were finally picked
up as specific compounds for SCTF. The chemical for-
mulas calculated based on the accurate mass and MS
fragmentation pattern of these peaks were collated with the
phytochemical metabolite database, and we selected a
Fig. 13 Extracted ion chromatograms of SCTF and ACF samples at
m/z 663.38–663.40. Data taken from reference 30. Six samples of
SCTF were crude drugs of non-JP grade with dried fruit form. ACF-
101 and -102 were crude drugs of EP grade with dried fruit form.
ACF-103, -104, -105 and -106 were health food with capsule form.
The vertical axes represent the relative signal intensity to 60,000 and
6,000 for SCTF and ACF, respectively
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putative triterpene—ID 6436 (RT 4.59 min, m/z 663.3920,
formula C40H55O8 for [M-H]
−)—as the first target to
identify the chemical structure.
The SCTF crude drug was extracted with CHCl3 and
fractionated using normal and reversed-phase column
chromatography and prep-HPLC, monitoring the marker
compound on LC/MS as a guide to obtain compound 4.
Compound 4 was isolated as an amorphous colorless
powder, and its molecular formula was determined as
C40H56O8 by high-resolution electrospray ionization mass
spectrometry, with 13 degrees of unsaturation. Its complete
structure was determined as 3-O-trans-feruloyl tormentic
acid on the basis of spectroscopic data from 1H-NMR, 13C-
NMR, and HMQC and HMBC analyses (Tables 5, 6;
Fig. 12); this is the first time that this compound has been
isolated from a Vitex plant.
We also analyzed additional SCTF and ACF products by
LC/MS to evaluate the usefulness of compound 4 as a
marker compound for SCTF and successfully verified its
specificity (Fig. 13; Table S5). The limit of detection of
compound 4 in SCTF raw materials was 0.02 mg/ml. These
results demonstrated that monitoring a marker compound
for SCTF—3-O-trans-feruloyl tormentic acid—should help
prevent the use of adulterated materials in ACF products,
and would also be a useful means of identifying the origin
of raw materials in SCTF products.
Future perspective
With the changes in cause-specific morbidity and the
increasing interest in self-medication, Western herbs are
becoming popular in Japan. Because herbal products and
their ingredients contain thousands of constituents, the
authentication of original species from herbal products is
the first and most important task to ensure their quality and
thus their safety and efficacy. This review described the
importance of quality control in the regulation of herbal
products, using Cimicifuga and Vitex products as examples.
There are many other Western herbs being developed for
OTC drugs, foods with functional claims and health foods,
and the proper use of the correct origin for each herb is
necessary. It is important to continue to work on the quality
control of herbal products from the viewpoint of regulatory
science.
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